- Home
- VFC vs TGTX Comparison
VFC vs TGTX Comparison
Compare VFC & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VFC
- TGTX
- Stock Information
- Founded
- VFC 1899
- TGTX 1993
- Country
- VFC United States
- TGTX United States
- Employees
- VFC N/A
- TGTX N/A
- Industry
- VFC Apparel
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- VFC Consumer Discretionary
- TGTX Health Care
- Exchange
- VFC Nasdaq
- TGTX Nasdaq
- Market Cap
- VFC 4.9B
- TGTX 4.2B
- IPO Year
- VFC N/A
- TGTX 1995
- Fundamental
- Price
- VFC $15.13
- TGTX $29.33
- Analyst Decision
- VFC Buy
- TGTX Strong Buy
- Analyst Count
- VFC 18
- TGTX 4
- Target Price
- VFC $16.33
- TGTX $42.50
- AVG Volume (30 Days)
- VFC 8.3M
- TGTX 2.9M
- Earning Date
- VFC 10-27-2025
- TGTX 08-04-2025
- Dividend Yield
- VFC 2.38%
- TGTX N/A
- EPS Growth
- VFC N/A
- TGTX N/A
- EPS
- VFC N/A
- TGTX 0.36
- Revenue
- VFC $9,496,297,000.00
- TGTX $454,069,000.00
- Revenue This Year
- VFC $1.64
- TGTX $82.58
- Revenue Next Year
- VFC $2.85
- TGTX $44.99
- P/E Ratio
- VFC N/A
- TGTX $81.30
- Revenue Growth
- VFC N/A
- TGTX 30.96
- 52 Week Low
- VFC $9.41
- TGTX $21.11
- 52 Week High
- VFC $29.02
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- VFC 73.08
- TGTX 44.34
- Support Level
- VFC $12.60
- TGTX $27.23
- Resistance Level
- VFC $15.57
- TGTX $29.17
- Average True Range (ATR)
- VFC 0.49
- TGTX 0.85
- MACD
- VFC 0.25
- TGTX 0.43
- Stochastic Oscillator
- VFC 87.78
- TGTX 87.47
About VFC V.F. Corporation
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of 11 brands includes Vans, The North Face, Timberland, Altra, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.